Alnylam's Vutrisiran Shows Mixed Results in Cardiomyopathy Study

The heart disease drug met primary goals but fell short of investor expectations, leading to a significant stock drop.

Vutrisiran reduced all-cause mortality and cardiovascular events by 28% overall in a 42-month study.
The drug met all primary and secondary endpoints, but results were complicated by patients using Pfizer's Vyndaqel.
Investors expected a 32% reduction in risk at 30 months, but the actual figure was 13.8%.
Alnylam's stock fell over 7% after the detailed data were presented at the European Society of Cardiology Congress.
Despite the mixed results, analysts believe Vutrisiran will still be competitive in the growing cardiomyopathy market.